| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/06/2005 | US20050004116 Triazole inhibitors of type 2 methionine aminopeptidase |
| 01/06/2005 | US20050004112 C-fms kinase inhibitors |
| 01/06/2005 | US20050004110 Inhibitors of glycogen synthase kinase-3 (gsk-3) and aurora-2, both serine/threonine protein kinases; for treating diseases such as cancer, diabetes and alzheimer's disease |
| 01/06/2005 | US20050004109 Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia |
| 01/06/2005 | US20050004088 Hormonal contraceptive product |
| 01/06/2005 | US20050004082 Ether compounds |
| 01/06/2005 | US20050004081 Pharmaceutical combinations for the treatment of cancer |
| 01/06/2005 | US20050004068 Modulation of tor |
| 01/06/2005 | US20050004061 Immunostimulatory nucleic acid molecules |
| 01/06/2005 | US20050004056 Ptp10d, tec protein tyrosine kinase and edtp homologous proteins involved in the regulation of energy homeostasis |
| 01/06/2005 | US20050004037 Osteogenic growth oligopeptides as stimulants of hematopoiesis |
| 01/06/2005 | US20050004035 Antiinflammatory agents; multiple sclerosis; inflamamtory bowel disorders; antitumor agents; sepsis |
| 01/06/2005 | US20050004018 Use of antitumoral compound in cancer therapy |
| 01/06/2005 | US20050004012 Use of aplidine for the treatment of pancreatic cancer |
| 01/06/2005 | US20050004010 Complex with antitumor agents; therapy, diagnosis |
| 01/06/2005 | US20050004009 Peptidomimetic inhibitors of STAT activity and uses thereof |
| 01/06/2005 | US20050003490 Immunoglobulins specific for cell surface protein for use in diagnosis, prevention and treatment of cell proliferative disorders; inhibitory action associated with reduced cellular transport of amino acids |
| 01/06/2005 | US20050003473 Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase |
| 01/06/2005 | US20050003467 Such as epiephrine which is contacted with blood vessel that feeds nutrients to tumor tissue, and hemolyzing red blood cells; drug screening |
| 01/06/2005 | US20050003465 Monoclonal abtibody specific to prostate cell-surface antigen associated with androgen-dependent and androgen-independent prostate tumors for use in prevention, diagnosis and treatment of cell proliferative disorders; immunodiagnostics; immunotherapy |
| 01/06/2005 | US20050003463 Method and nucleic acids for the analysis of colorectal cell proliferative disorders |
| 01/06/2005 | US20050003460 Identifying progenitor cell populations comprising at least one disaccharide repeat of glucuronic acid and n-acetylglucosamine and enhanced hyaluronic acid synthase expression for use in tissue repair and treatment and prevention of cancer and/or skin disorders. |
| 01/06/2005 | US20050003453 G-CSF analog compositions and methods |
| 01/06/2005 | US20050003446 Peptide sequences for use in identification of modulators for use in treatment and prevention of inflammatory, cell proliferative, arteriosclerotic and skin disorders |
| 01/06/2005 | US20050003425 Nucleotide sequences coding tumor marker protein for use in diagnosis and/or prognosis of cell proliferative disorders |
| 01/06/2005 | US20050003412 Protein activator of superoxide production for use in treatment and prevention of cancer, psoriasis, prostatic hypertrophy, benign prostatic hypertrophy and cardiovascular disease |
| 01/06/2005 | US20050003370 Expression vector comprising nucleotide sequences coding membrane receptor proteins for use in identifying modulators for treatment and prevention of cell proliferative, nervous system, reproductive cardiovascular and inflammation disorders |
| 01/06/2005 | US20050003353 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 01/06/2005 | US20050003352 Comprises recombinant mitochondrial transport protein for diagnosis, prevention and treatment of alzheimer's, diabetes, parkinson's, huntington's, cancers |
| 01/06/2005 | US20050003031 Anti-cancer compounds |
| 01/06/2005 | US20050002965 Recombinant adenovirus with enhanced therapeutic effect and pharmaceutical composition comprising said recombinant adenovirus |
| 01/06/2005 | US20050002951 Novel method of inducing antigen-specific t cells |
| 01/06/2005 | US20050002940 Cancerous disease modifying antibodies |
| 01/06/2005 | US20050002938 To screen for inhibitors of cell growth and to develop small molecule therapeutics for treating cancers |
| 01/06/2005 | US20050002936 Methods and compositions useful for inhibition of angiogenesis |
| 01/06/2005 | US20050002928 Treatment with anti-ErbB2 antibodies |
| 01/06/2005 | US20050002920 Collecting, activating, culturing and optionally expanding peripheral blood mononuclear cells then hypomethylating with 5-aza-cytidine or 5-aza-2'-deoxycytidine |
| 01/06/2005 | US20050002918 Selective treatment of IL-13 expressing tumors |
| 01/06/2005 | US20050002908 Method for producing a recombinant adeno-associated virus, suitable means therefor and use for producing a medicament |
| 01/06/2005 | US20050002906 Preferentially amplifying in tumors following cancer cell activation of specific gene regulatory region |
| 01/06/2005 | US20050002900 Inhibiting estradiol production in human adipocytes using interferon gamma and/or tumor necrosis factor antagonist and/or interleukin-1 antagonist; reducing side effects |
| 01/06/2005 | CA2531107A1 Inhibitors of histone deacetylases for the suppression therapy of diseases |
| 01/06/2005 | CA2531101A1 Topical use of valproic acid for the prevention or treatment of skin disorders |
| 01/06/2005 | CA2530668A1 Product containing at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent |
| 01/06/2005 | CA2530662A1 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof |
| 01/06/2005 | CA2530582A1 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis |
| 01/06/2005 | CA2530311A1 Cancer treatment with epothilones |
| 01/06/2005 | CA2530184A1 Method of selecting patients suitable for wt1 vaccine |
| 01/06/2005 | CA2530125A1 Use of double-stranded ribonucleic acid for inducing cell lysis |
| 01/06/2005 | CA2529943A1 Peptides derived from the protein mmp-2, and the use thereof in antitumoral immunotherapy |
| 01/06/2005 | CA2529930A1 Biologically active neopeltolide compounds |
| 01/06/2005 | CA2529840A1 Therapeutic agent for soft tissue sarcoma |
| 01/06/2005 | CA2529371A1 Cytotoxic depsipeptides |
| 01/06/2005 | CA2529145A1 Nucleic acid sequences encoding and compositions comprising ige signal peptide and/or il-15 and methods for using the same |
| 01/06/2005 | CA2529083A1 Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| 01/06/2005 | CA2528152A1 Compositions and methods for treatment of disease with acetylated disaccharides |
| 01/06/2005 | CA2527689A1 Recombinant anti-cd30 antibodies and uses thereof |
| 01/06/2005 | CA2526085A1 Treatment with anti-vegf antibodies |
| 01/05/2005 | EP1493812A2 A truncated keratinocyte growth factor (KGF) having increased biological activity |
| 01/05/2005 | EP1493745A1 New crystalline and amorphous form of a triazolo(4,5-D)pyrimidine compound |
| 01/05/2005 | EP1493741A2 Benzo[b]thiophene compounds, intermediates, processes, compositions and methods |
| 01/05/2005 | EP1493740A1 5-fluoro-thiophene compounds, the process for their prepartion, the pharmaceutical compositions containing them and their use as metalloproteinases inhibitors |
| 01/05/2005 | EP1493738A1 Epothilone derivatives |
| 01/05/2005 | EP1493033A2 Sc6 for diagnosis of hypoxia related conditions |
| 01/05/2005 | EP1493028A2 Phage displayed pdz domain ligands |
| 01/05/2005 | EP1492884A2 Methods of diagnosing and treating colorectal cancer |
| 01/05/2005 | EP1492876A1 Cationic amphiphiles for intracellular delivery of therapeutic molecules, composition, process and use thereof |
| 01/05/2005 | EP1492871A2 Cancer associated protein kinases and their uses |
| 01/05/2005 | EP1492868A2 Method of modulating inflammatory response |
| 01/05/2005 | EP1492819A2 Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine |
| 01/05/2005 | EP1492813A2 Ox40r binding agents |
| 01/05/2005 | EP1492793A1 New-4-(pyrrolopyrimidin-6-yl)benzenesulphonamide derivatives |
| 01/05/2005 | EP1492792A2 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino 4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments |
| 01/05/2005 | EP1492789A1 Tropane derivatives as ccr5 modulators |
| 01/05/2005 | EP1492782A1 Piperazinyl- or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase |
| 01/05/2005 | EP1492780A1 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as ptpase 1b inhibitors |
| 01/05/2005 | EP1492779A1 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity |
| 01/05/2005 | EP1492778A1 (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors |
| 01/05/2005 | EP1492777A1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidase inhibitors |
| 01/05/2005 | EP1492775A2 Oxo-azabicyclic compounds |
| 01/05/2005 | EP1492774A2 Pyrimidone derivatives useful for the treatment of inflammation and immunological diseases |
| 01/05/2005 | EP1492773A2 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation |
| 01/05/2005 | EP1492772A1 Farnesyl protein transferase inhibitors as antitumor agents |
| 01/05/2005 | EP1492771A1 Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents |
| 01/05/2005 | EP1492766A1 Improved cc-1065 analog synthesis |
| 01/05/2005 | EP1492596A1 Depsipeptide for therapy of kidney cancer |
| 01/05/2005 | EP1492568A1 Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor |
| 01/05/2005 | EP1492567A1 Formulations and methods of using nitric oxide mimetics in cancer treatment |
| 01/05/2005 | EP1492566A2 Binding agents and their use in targeting tumor cells |
| 01/05/2005 | EP1492562A2 Virus-like particles of human papillomavirus |
| 01/05/2005 | EP1492561A1 Methods for treating mammary gland disorders |
| 01/05/2005 | EP1492560A2 Use of interleukin-19 to treat cervical cancer |
| 01/05/2005 | EP1492559A2 Truncated 24 kda basic fibroblast growth factor |
| 01/05/2005 | EP1492556A1 Use of long pentraxin ptx3 for the treatment of fgf-8 mediated tumour diseases |
| 01/05/2005 | EP1492554A2 Spherical protein particles and methods of making and using them |
| 01/05/2005 | EP1492542A1 Hormone replacement therapy |
| 01/05/2005 | EP1492536A1 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors |
| 01/05/2005 | EP1492534A1 Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors |
| 01/05/2005 | EP1492530A1 Thiazol-2-yl-imine compounds as pde-7 inhibitors |
| 01/05/2005 | EP1492526A2 Improved prodrugs of cc-1065 analogs |